ETRA Stock Forecast & Price Target

Electra Therapeutics is attractive because its SIRP-targeted platform is first-in-class and has already shown proof-of-concept in humans, suggesting a differentiated mechanism that can selectively deplete pathogenic myeloid and T cells while preserving normal immune function. The lead asset ipsoprubart has produced highly compelling early efficacy in secondary HLH, including 100% eight-week overall survival and 100% overall response in 12 frontline malignancy-associated HLH patients, while also benefiting from FDA Breakthrough Therapy and EMA PRIME designations and a registrational program already underway. The opportunity is reinforced by a large, underpenetrated orphan market with about 12,600 U.S. diagnoses in 2025, potential growth toward nearly 17,500 by 2028, and premium pricing potential above $1M per patient annually, while the company’s cash and IPO net proceeds are expected to fund operations into 2029.

Electra Therapeutics is viewed negatively because it has no approved products and remains heavily dependent on costly late-stage development, with projected R&D of $86.5 million in 2026 and $120 million in 2027, operating losses of $108.5 million and $160 million, and free cash outflows of about $105.4 million and $154.8 million. Its lead program faces substantial clinical, regulatory, and commercial uncertainty: ipsoprubart’s data are still based on small, uncontrolled studies, the pivotal 1L secondary HLH trial is not expected to complete enrollment until 2H27 with data in 1H28, and approval may depend on an external control and additional follow-up. Even if approved, uptake could be limited by competition from established therapies, payer resistance, manufacturing and supply demands, and the risk that later development or commercialization will require additional financing and dilution.